论文部分内容阅读
常规的消炎痛三剂疗法治疗早产儿症状性动脉导管未闭(sPDA)合并呼吸道疾病时,复发率很高,约3O%病例再发生在到右的分流。作者在3次连续性对照研究中发现,消炎痛给药后10小时引起导管收缩的血清浓度约1.0μg/ml。延长消炎痛治疗使浓度维持在0.5μg/ml,对抑制两种血管扩张性前列腺素PGI_2及PGE_2是有效的。病人及方法前瞻性研究1982～1985年西德一组32名早产儿sPDA,出生体重650～2900克,胎龄25～34周。试用消炎痛分为负荷期、维持期及清除期。治疗开始剂量为0.2mg/kg,肌注,每次间隔12小时,继续用2次,试图在此负荷期的第3次投药后
Conventional indomethacin three-dose therapy for symptomatic patent ductus arteriosus (sPDA) in preterm infants with respiratory disease, the recurrence rate is high, about 3O% of cases re-occurred in the right shunt. In a series of 3 consecutive controlled studies, the authors found that serum concentrations of catheter contractions at 10 hours after indomethacin administration were about 1.0 μg / ml. Prolonged indomethacin treatment at a concentration of 0.5 μg / ml is effective in inhibiting the two vasodilator prostaglandins PGI_2 and PGE_2. Patients and Methods Prospective study of 1982-1985 West Germany a group of 32 preterm children with sPDA, birth weight 650 ~ 2900 grams, gestational age 25 to 34 weeks. Trial indomethacin divided into load, maintenance and removal period. Treatment start dose of 0.2mg / kg, intramuscular injection, each interval of 12 hours, continue with 2 times, trying to load the third time after the dosing